NuCana gets FDA’s orphan drug designation for acelarin

NuCana (NASDAQ:NCNA) received the FDA’s orphan drug designation for acelarin, a nucleoside analog of gemcitabine, for the treatment of biliary tract cancer.

“There is a high unmet need for patients suffering from this cancer type,” Hugh Griffith, NuCana’s founder and CEO, said in a statement.

“Our Phase Ib study of acelarin combined with cisplatin showed an approximate doubling of the response rate expected with the standard of care, gemcitabine plus cisplatin, with several patients achieving significant reductions in their tumor volume as well as further tumor shrinkage over time,” he added.

Acelarin is also being evaluated in a Phase 2 and Phase 3 study for patients with ovarian and pancreatic cancer, respectively.

NuCana plans to initiate a Phase 3 study of acelarin in combination with cisplatin as a front-line treatment for patients with biliary tract cancer later this year.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.